Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma

Hates-Jordan A, Doherty DK, West SD, Raney RB, Blakely ML, Cox CS Jr, et al. Outcome after surgical resection of recurrent rhabdomyosarcoma. J Pediatr 2006;41:633–638.

McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. Am J Roentogenol 2005;184:1293–304.

Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AM, Molenaar WM, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257–261.

Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff DA, et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4:1215–1220.

Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumors: comparison with bone scintigraphy. Eur J Nucl Med 2000;27:1305–1311.

Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, Mechtersheimer G, Willeke F, Bockler D, et al. Clinical value of [18-F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000;231:380–386.

Klem ML, Grewal RK, Wexler LH, Schoder H, Meyers PA, Wolden SL. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 2007;29:9–14.

Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Glut-1 expression and enhanced glucose metabolism are associated with tumor grade in bone and soft tissue sarcomas: a prospective evaluation by [F-18]-fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:683–691.

Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200–1209.

Rodary C, Flamant F, Donaldson SS. An attempt to use a common staging system in rhabdomyosarcoma: a report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP). Med Pediatr Oncol 1989;17:210–215.

Ben Arush MW, Bar Shalom R, Postovsky S, Militianu D, Haimi M, Zaidman I, et al. Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol 2006;28:440–445.

Peng F, Rabkin G, Muzik O. Use of 2-deoxy-2-[F-18]-fluoro-d-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study. Clin Nucl Med 2006;31:394–397.

Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 2005;103:2391–2396.

Rich DC, Corporon CA, Smith MB, Black CT, Lally KP, Andrassy RJ. Second malignant neoplasms in children after treatment of soft tissue sarcoma. J Pediatr Surg 1997;32:369–372.

Tateishi U, Hasegawa T, Miyakawa K, Sumi M, Moriyama N. CT and MRI features of recurrent tumors and second primary neoplasms in pediatric patients with rhabdomyosarcoma. Am J Roentogenol 2003;181:879–84.